SAFETY AND EFFECTIVENESS OF INTRAARTICULAR ADMINISTRATION OF ADIPOSE-DERIVED STROMAL VASCULAR FRACTION FOR TREATMENT OF KNEE ARTICULAR CARTILAGE DEGENERATIVE DAMAGE: PRELIMINARY RESULTS OF A CLINICAL TRIAL

封面

如何引用文章

全文:

详细

The incidence of knee osteoarthritis tends to increase every year and constitutes more than 83% of overall OA morbidity. Moreover, the OA morbidity among younger patients is also increasing. However, currently available treatment methods do not provide quite satisfactory outcomes.

Purpose of the study – to evaluate safety and efficacy of intraarticular introduction of autologous adipose-derived stromal vascular fraction for treatment of knee osteoarthritis.

Material and methods. By the moment of writing the present report, 28 patients were included into the study. All patients underwent tumescent liposuction under local anesthesia. The stromal vascular fraction was isolated from lipoaspirate within 1,5 hours after harvesting and subsequently injected into the articular cavity. Follow-up period was 6 months after injections. The authors report on efficacy data of 10 patients who completed the study according to protocol and safety data of all 28 patients. Efficacy was evaluated basing on laboratory assessments and patient’s subjective assessment by validated questionnaires.

Results. Neither adverse reactions no adverse events were observed. Significant decrease of pain severity by VAS was noted in one week after injection and pain score continued decreasing during the whole follow up period. The increase of KOOS score was noted starting on the fifth week after injection. KSS part 1 score increased in 8 weeks, KSS part 2 score — in 6 months after injection. Physical health, assessed with SF-36 questionnaire significantly improved in 2 and 6 months after the procedure. There was a clear trend towards improvement of mental health.

Conclusion. Preliminary results of clinical study suggest intraarticular injection of autologous adipose-derived stromal vascular fraction to be a safe and efficient method of the treatment of knee osteoarthritis. 

作者简介

I. Smyshlyaev

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation;
Central State Medical Academy, Administrative Department of the President of the Russian Federation

编辑信件的主要联系方式.
Email: mutant89@rambler.ru

Ivan A. Smyshlyaev — Orthopedic Surgeon, Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation; Graduate Student, Central State Medical Academy, Administrative Department of the President of the Russian Federation 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

S. Gilfanov

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation;
Central State Medical Academy, Administrative Department of the President of the Russian Federation;
Peoples’ Friendship University of Russia

Email: fake@neicon.ru
Sergey I. Gilfanov — Dr. Sci. (Med.), professor, Head of the Traumatology and Orthopedics Department, Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation; Head of Chair of Traumatology and Orthopedics, Central State Medical Academy, Administrative Department of the President of the Russian Federation; Peoples’ Friendship University of Russia 俄罗斯联邦

V. Kopylov

Orenburg City Clinical Hospital N 4

Email: fake@neicon.ru

Vadim A. Kopylov — Cand. Sci. (Med.), Head of the Surgic Department 

11, ul. Postnikova, Orenburg, 460000

俄罗斯联邦

R. Gilmutdinov

Orenburg Regional Clinical Donor Blood Center

Email: fake@neicon.ru

Rinat G. Gilmutdinov — Cand. Sci. (Med.), Chief Medical Officer 

32, ul. Aksakova, Orenburg, 460018

俄罗斯联邦

I. Pulin

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Andrey A. Pulin — Cand. Sci. (Med.), Head of the Laboratory of Cell Technologies of the Center for Biomedical Technologies 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

I. Korsakov

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Ivan N. Korsakov — Cand. Sci. (Med.), Head of the Laboratory of Tissue Engeeniring of the Center for Biomedical Technologies 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

I. Gilmutdinova

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Ilmira R. Gilmutdinova — Cand. Sci. (Med.), transfusiologist of Cryobank of the Center for Biomedical Technologies 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

A. Petrikina

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Anastasiya P. Petrikina – Laboratory Diagnostics Laboratory of Cell Technologies of the Center for Biomedical Technologies 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

P. Eremin

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Petr S. Eremin – Biologist of Laboratory of Cell Technologies of the Center for Biomedical Technologies 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

O. Kruchkova

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Oksana V. Kruchkova – Cand. Sci. (Med.), Head of the Department of X-ray Diagnostics and Tomography 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

V. Abeltsev

Joined Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Vladimir P. Abeltsev — Dr. Sci. (Med.), professor Head of the Department of Traumatology and Orthopedics 

6, Michurinskii pr-t, Moscow,119285

俄罗斯联邦

N. Zagorodniy

Peoples’ Friendship University of Russia

Email: fake@neicon.ru

Nikolay V. Zagorodniy — Dr. Sci. (Med.), professor, Head of the Department of Traumatology and Orthopedics 

6, ul. Miklukho-Maklaya, Moscow, 117198

俄罗斯联邦

V. Zorin

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Vadim L. Zorin – Cand. Sci. (Biol.), biologist of Laboratory of Cell Technologies of the Center for Biomedical Technologies 

15, ul. Marshala Timoshenko, Moscow, 121359

俄罗斯联邦

V. Vasilyev

South Ural State Medical University

Email: fake@neicon.ru

Vyacheslav S. Vasilyev – Cand. Sci. (Med.), Assistant of the Department of Plastic Surgery and Cosmetology 

64, ul. Vorovskogo, Chelyabinsk, 454048

俄罗斯联邦

D. Pupynin

Orenburg City Clinical Hospital N 4

Email: fake@neicon.ru

Dmitry Yu. Pupynin — Chief Medical Officer 

11, ul. Postnikova, Orenburg, 460000

俄罗斯联邦

I. Eremin

Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation;
Central State Medical Academy, Administrative Department of the President of the Russian Federation

Email: fake@neicon.ru

Il’ya I. Eremin – Cand. Sci. (Med.), Head of Center for Biomedical Technologies, Central Clinical Hospital with Outpatient Health Center, Administrative Department of the President of the Russian Federation; Assistant Professor, Department of Health Organization and Public health, restorative medicine and medical rehabilitation, Central State Medical Academy, Administrative Department of the President of the Russian Federation

俄罗斯联邦

参考

  1. Vos T., Barber R.M., Bell B., Bertozzi-Villa A., Biryukov S., Bolliger I. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4.
  2. Lohmander L.S. Knee replacement for osteoarthritis: facts, hopes, and fears. Medicographia 2013;35:181-188.
  3. Srikanth V.K., Fryer J.L., Zhai G., Winzenberg T.M., Hosmer D., Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13:769781. doi: 10.1016/j.joca.2005.04.014.
  4. Kleemann R.U., Krocker D., Cedraro A., Tuischer J., Duda G.N. Altered cartilage mechanics and histology in knee osteoarthritis: relation to clinical assessment (ICRS Grade). Osteoarthritis Cartilage. 2005;13:958-963. doi: 10.1016/j.joca.2005.06.008.
  5. Loeser R.F., Goldring S.R., Scanzello C.R., Goldring M.B.. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum. 2012;64:1697-1707. doi: 10.1002/art.34453.
  6. Morrison J.B. The mechanics of the knee joint in relation to normal walking. J Biomech. 1970;3:5-61.
  7. Yucesoy B., Charles L.E., Baker B., Burchfiel C.M. Occupational and genetic risk factors for osteoarthritis: a review. Work. 2015;50:261-273. doi: 10.3233/WOR-131739.
  8. Messier S.P., Loeser R.F., Miller G.D., Morgan T.M., Rejeski W.J., Sevick M.A., Ettinger W.H., Pahor M., Williamson J.D. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum. 2004; 50:1501-1510. doi: 10.1002/art.20256.
  9. Turk D.C., Wilson H.D., Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377:2226-2235. doi: 10.1016/S0140-6736(11)60402-9.
  10. Pak J., Lee J.H., Park K.S., Park M., Kang L.W., Lee S.H. Current use of autologous adipose tissue-derived stromal vascular fraction cells for orthopedic applications. J Biomed Sci. 2017;24(1):9. doi: 10.1186/s12929-017-0318-z.
  11. Sato M., Uchida K., Nakajima H., Miyazaki T., Guerrero A.R., Watanabe S., Roberts S., Baba H. Direct transplantation of mesenchymal stem cells into the knee joints of Hartley strain guinea pigs with spontaneous osteoarthritis. Arthritis Res Ther. 2012;14:R31. doi: 10.1186/ar3735.
  12. Black L.L., Gaynor J., Gahring D., Adams C., Aron D., Harman S., Gingerich D.A., Harman R. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther. 2007;8:272-284.
  13. Koga H., Shimaya M., Muneta T., Nimura A., Morito T., Hayashi M., Suzuki S., Ju Y.J., Mochizuki T., Sekiya I. Local adherent technique for transplanting mesenchymal stem cells as a potential treatment of cartilage defect. Arthritis Res Ther. 2008;10:R84. doi: 10.1186/ar2460.
  14. Strioga M., Viswanathan S., Darinskas A., Slaby O., Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012;21:2724-2752. doi: 10.1089/scd.2011.0722.
  15. Centeno C.J., Schultz J.R., Cheever M., Freeman M., Faulkner S., Robinson B., Hanson R. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2011; 6:368-378. doi: 10.2174/157488811797904371.
  16. Zuk P.A., Zhu M., Ashjian P. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279-4295. doi: 10.1091/mbc.E02-02-0105.
  17. Yoshimura K., Suga H., Eto H. Adipose-derived stem/ progenitor cells: roles in adipose tissue remodeling and potential use for soft tissue augmentation. Regen Med. 2009;4:265-273. doi: 10.2217/17460751.4.2.265.
  18. Bui K.H., Duong T.D., Nguyen T.N., Nguyen T.D., Le V.T., Mai V.T., Phan N.L., Le D.M., Ngoc N.K., Phan P.V. Symptomatic knee osteoarthritis treatment using autologous adipose derived stem cells and platelet-rich plasma: a clinical study. Biomed Res Ther. 2014;1:2-8. doi: 10.7603/s40730-014-0002-9.
  19. Koh Y.G., Choi Y.J., Kwon S.K., Kim Y.S., Yeo J.E. Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2015; 23(5):1308-1316. doi: 10.1007/s00167-013-2807-2.
  20. Zuk P.A., Zhu M., Muzino H., Huang J., Futrell J.W., Katz A.J., Benhaim P., Lorenz H.P., Hedrick M.H. Multilineage cells from human adipose tissue: implication for cell-based therapies. Tissue Eng. 2001;7(2):211-228. doi: 10.1089/107632701300062859.
  21. Vangsness C.T., Farr J., Boyd J., Dellaero D.T., Mills C.R., LeRoux-Williams M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. 2014; 96:90-98. doi: 10.2106/JBJS.M.00058.
  22. Bernardo M.E., Locatelli F., Fibbe W.E. Mesenchymal stromal cells: a novel treatment modality for tissue repair. Ann N Y Acad Sci. 2009;1176:101-117. doi: 10.1111/j.1749-6632.2009.04607.x
  23. Guilak F., Awad H.A., Fermor B., Leddy H.A., Gimble J.M. Adipose-derived adult stem cells for cartilage tissue engineering. Biorheology. 2004;41:389-399.
  24. Murphy J.M., Fink D.J., Hunziker E.B., Barry F.P. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48:3464-3474. doi: 10.1002/art.11365.
  25. Cole B.J., Karas V., Hussey K., Pilz K., Fortier L.A. Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis. Am J Sports Med. 2017;45(2):339-346. doi: 10.1177/0363546516665809.
  26. Goncars V., Jakobsons E., Blums K., Briede I., Patetko L., Erglis K., Erglis M., Kalnberzs K., Muiznieks I., Erglis A. The comparison of knee osteoarthritis treatment with single-dose bone marrow-derived mononuclear cells vs. hyaluronic acid injections. Medicina (Kaunas). 2017; 53(2):101-108. doi: 10.1016/j.medici.2017.02.002.
  27. de Girolamo L., Grassi M., Viganò M., Orfei C.P., Montrasio U.A., Usuelli F. Treatment of achilles tendinopathy with autologous adipose-derived stromal vascular fraction: results of a randomized prospective clinical trial. Orthop J Sports Med. 2016;4(7 suppl 4): 2325967116S001
  28. doi: 10.1177/2325967116S00128. 28. Lee S.Y., Kim W., Lim C., Chung S.G. Treatment of lateral epicondylosis by using allogeneic adipose-derived mesenchymal stem cells: a pilot study. Stem Cells. 2015; 33(10):2995-3005. doi: 10.1002/stem.2110.
  29. Yubo M., Yanyan L., Li L., Tao S., Bo L., Lin C. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: A meta-analysis. PLoS One. 2017;12(4):e0175449. doi: 10.1371/journal.pone.0175449.
  30. Nakagami H., Maeda K., Morishita R., Iguchi S., Nishikawa T., Takami Y., Kikuchi Y., Saito Y., Tamai K., Ogihara T., Kaneda Y. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol. 2005;25(12):2542-2547. doi: 10.1161/01.ATV.0000190701.92007.6d.
  31. Cai L., Johnstone B.H., Cook T.G., Liang Z., Traktuev D., Cornetta K., Ingram D.A., Rosen E.D., March K.L. Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells. 2007; 25(12):3234-3243. doi: 10.1634/stemcells.2007-0388.
  32. Mizuno K., Muneta T., Morito T., Ichinose S., Koga H., Nimura A., Mochizuki T., Sekiya I. Exogenous synovial stem cells adhere to defect of meniscus and differentiate into cartilage cells. J Med Dent Sci. 2008;55(1): 101-111.
  33. Ong E., Chimutengwende-Gordon M., Khan W. Stem cell therapy for knee ligament, articular cartilage and meniscal injuries. Curr Stem Cell Res Ther. 2013;8(6):422-428.
  34. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076-1084. doi: 10.1002/jcb.20886.
  35. Yeo R.W.Y., Lai R.C., Tan K.H., Lim S.K. Exosome: A novel and safer therapeutic refinement of mesenchymal stem cell. Exosomes Microvesicles. 2013;1(7):1-12. doi: 10.5772/57460.
  36. Еремин И.И., Бозо И.Я., Воложин Г.А., Деев Р.В., Рожков С.И., Еремин П.С., Комлев В.С., Зорин В.Л., Пулин А.А., Тимашков Д.А., Витько Н.К., Котенко К.В. Биологическое действие тканеинженерных костных графтов из трикальция фосфата и мультипотентных мезенхимальных стромальных клеток в ортотопических условиях in vivo. Кремлевская медицина. Клинический вестник. 2015;(4):144-150. Eremin I.I., Bozo I.Ya., Volozhin G.A., Deev R.V., Rozshkov S.I., Eremin P.S., Komlev V.S., Zorin V.L., Pulin A.A., Timashkov D.A., Vit’ko N.K., Kotenko K.V. [Biological action of tissue engineered bone grafts made of tricalcium phosphate and multipotent mesenchymal stromal cells in orthotopic conditions in vivo]. Kremlevskaya meditcina. Klinicheskii vestnik [Kremlin Medicine. Clinical Herald]. 2015;(4):144-150. (in Russian).
  37. Еремин И.И., Бозо И.Я., Воложин Г.А., Деев Р.В., Рожков С.И., Еремин П.С., Комлев В.С., Зорин В.Л., Пулин А.А., Тимашков Д.А., Витько Н.К., Котенко К.В. Возможности применения тканеинженерных костных графтов в челюстно-лицевой хирургии. Кремлевская медицина. Клинический вестник. 2015;(4):151-157. Eremin I.I., Bozo I.Ya., Volozhin G.A., Deev R.V., Rozshkov S.I., Eremin P.S., Komlev V.S., Zorin V.L., Pulin A.A., Timashkov D.A., Vit’ko N.K., Kotenko K.V. [Possibilities of clinical application of tissue engineered bone grafts in craniofacial surgery]. Kremlevskaya meditcina. Klinicheskii vestnik [Kremlin Medicine. Clinical Herald]. 2015;(4): 151-157. (in Russian).
  38. Domergue S., Bony C., Maumus M., Toupet K., Frouin E., Rigau V., Vozenin M.C., Magalon G., Jorgensen C., Noël D. Comparison between stromal vascular fraction and adipose mesenchymal stem cells in remodeling hypertrophic scars. PLoS One. 2016;11(5):e0156161. doi: 10.1371/journal.pone.0156161.
  39. Dykstra J.A., Facile T., Patrick R.J., Francis K.R., Milanovich S., Weimer J.M., Kota D.J. Concise review: fat and furious: harnessing the full potential of adiposederived stromal vascular fraction. Stem Cells Transl Med. 2017;6(4):1096-1108. doi: 10.1002/sctm.16-0337.
  40. Yoshimura K., Sato K., Aoi N., Kurita M., Hirohi T., Harii K. Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/ Stromal Cells. Aesthetic Plast Surg 2008;32(1):48-55. doi: 10.1007/s00266-007-9019-4.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Traumatology and Orthopedics of Russia, 2023

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».